Prometheus Biosciences Inc (RXDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2016 | 12-2015 | 09-2015 | 06-2015 | 03-2015 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -25,492 | -92,458 | -51,247 | -36,626 | -23,507 |
| Depreciation Amortization | 986 | 2,575 | 1,659 | 926 | 439 |
| Accounts payable and accrued liabilities | 2,461 | 2,856 | 2,271 | 797 | 869 |
| Other Working Capital | 2,325 | 7,082 | 1,771 | 2,533 | 303 |
| Other Operating Activity | -484 | 29,145 | 14,155 | 13,689 | 12,396 |
| Operating Cash Flow | $-20,204 | $-50,800 | $-31,391 | $-18,681 | $-9,500 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -713 | -3,522 | -2,562 | -2,080 | -642 |
| Purchase Of Investment | -33,177 | -148,111 | -116,908 | -85,354 | -19,333 |
| Sale Of Investment | 46,087 | 90,662 | 80,260 | 41,533 | 24,775 |
| Investing Cash Flow | $12,197 | $-60,971 | $-39,210 | $-45,901 | $4,800 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 10,000 | 10,000 | N/A | N/A |
| Debt Repayment | -44 | N/A | -128 | -85 | N/A |
| Common Stock Issued | 15 | 141,980 | 111,950 | 111,877 | 41,440 |
| Other Financing Activity | 0 | -172 | 0 | 0 | -42 |
| Financing Cash Flow | $-29 | $151,808 | $121,822 | $111,792 | $41,398 |
| Beginning Cash Position | 46,383 | 6,346 | 6,346 | 6,346 | 6,346 |
| End Cash Position | 38,347 | 46,383 | 57,567 | 53,556 | 43,044 |
| Net Cash Flow | $-8,036 | $40,037 | $51,221 | $47,210 | $36,698 |
| Free Cash Flow | |||||
| Operating Cash Flow | -20,204 | -50,800 | -31,391 | -18,681 | -9,500 |
| Capital Expenditure | -713 | -3,522 | -2,562 | -2,080 | -642 |
| Free Cash Flow | -20,917 | -54,322 | -33,953 | -20,761 | -10,142 |